OBIO Orchestra BioMed Holdings Forecast, Technical & Fundamental Analysis
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies... Show more
OBIO is expected to report earnings to rise 42.42% to -46 cents per share on August 18
Q2'26
Est.
$-0.47
Q1'26
Beat
by $0.19
Q4'25
Beat
by $0.56
Q3'25
Beat
by $0.06
Q2'25
Missed
by $0.04
The last earnings report on May 12 showed earnings per share of -33 cents, beating the estimate of -51 cents. With 187.79K shares outstanding, the current market capitalization sits at 241.32M.
A.I.dvisor indicates that over the last year, OBIO has been loosely correlated with RXRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OBIO jumps, then RXRX could also see price increases.
OBIO in +7.39% Uptrend, rising for three consecutive days on May 19, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where OBIO advanced for three days, in of 217 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where OBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for OBIO just turned positive on June 04, 2026. Looking at past instances where OBIO's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
OBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OBIO as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for OBIO entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.858) is normal, around the industry mean (19.523). P/E Ratio (0.000) is within average values for comparable stocks, (35.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.680). OBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (6.636) is also within normal values, averaging (353.959).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
